Comparison of Jnj9375, a Thrombin Exosite 1-Directed Antibody, With Apixaban for Thromboprophylaxis After Elective Knee Replacement Surgery: Text-TKR Study

Weitz, Jeffrey I.; Raskob, Gary E.; Lassen, Michael R.; Segers, Annelise; Francis, Charles W.; Roberts, Robin S.; Fuji, Takeshi; Peters, Gary; Swaim, Renée M; Johnson, Maureen; Bernholz, Juliane; Lee, Michael; Strony, John

doi:10.1016/s0735-1097(19)32653-1

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, despite the promising preclinical animal efficacy and safety data, in a recently completed phase 2 randomized double-blind trial, JNJ-9375 was safe but less effective than apixaban in preventing thrombosis in patients undergoing knee replacement surgery when given postoperatively at doses of 0.1-1.8 mg/kg, i.v. (Weitz et al, 2019).The reason for the lack of efficacy is not clear, since the pharmacodymanic marker such as TT, a marker of anticoagulant activity, was elevated in a dosedependent manner. One possibility is that exosite 1 inhibition on thrombin in humans may not be an effective antithrombotic approach compared with what we have observed in rats.…”

Section: Discussionmentioning

confidence: 99%

Pharmacological Profile of JNJ-64179375: A Novel, Long-Acting Exosite-1 Thrombin Inhibitor

Devine

et al. 2019

J Pharmacol Exp Ther

View full text Add to dashboard Cite

JNJ-64179375 (JNJ-9375) is a recombinant human IgG4 monoclonal antibody engineered to mimic an IgA antibody that was identified in a patient who exhibited markedly prolonged clotting times but without spontaneous bleeding episodes over several years of follow-up. The crystal structure of the JNJ-9375 antigen-binding fragment/thrombin complex showed an almost identical binding mode to that of the patient IgA. In the current study, we characterized the in vitro and in vivo properties of JNJ-9375. Surface plasmon resonance studies demonstrated that JNJ-9375 binds to a-thrombin with high affinity and specificity (K D : 0.8 nM for human thrombin). JNJ-9375 produced concentration-dependent prolongation of in vitro clotting assays in human plasma, including thrombin time (TT), ecarin clotting time, prothrombin time, and activated partial thromboplastin time, with EC 2X values of 4.4, 12.4, 172.6, and 202.7 mg/ml, respectively. JNJ-9375 inhibited thrombin-induced platelet aggregation in human plasma with an IC 50 value of 52.6 nM (7.8 mg/ml) and produced concentration-dependent prolongation of reaction time tested by thromboelastography. JNJ-9375 pretreatment resulted in dose-dependent reduction in thrombus formation in the rat arteriovenous (AV) shunt model of thrombosis. Robust efficacy was observed at 0.3 mg/kg accompanied by 1.5Â of TT. Bleeding was increased at 3 mg/kg in a rat tail transection bleeding model demonstrating a therapeutic index of 10Â compared with 1Â for apixaban in the same models. Our data suggest that thrombin exosite I inhibition is efficacious against thrombosis in a pretreatment prevention animal model. SIGNIFICANCE STATEMENT JNJ-9375 is a novel, fully human monoclonal antibody that binds to the exosite I region of thrombin with high affinity and specificity. JNJ-9375 concentration dependently prolonged clotting times and inhibited thrombin-induced platelet aggregation in in vitro assays based on its mechanism of action. In an in vivo rat AV shunt model, JNJ-9375 prevented thrombus formation in a dose-dependent fashion while demonstrating reduced bleeding risk. The present study demonstrated the antithrombotic effects of inhibiting the exosite I region of thrombin when given in a prevention mode in preclinical animal models.

show abstract

Section: Discussionmentioning

confidence: 99%

Pharmacological Profile of JNJ-64179375: A Novel, Long-Acting Exosite-1 Thrombin Inhibitor

Devine

et al. 2019

J Pharmacol Exp Ther

View full text Add to dashboard Cite

show abstract

Comparison of Jnj9375, a Thrombin Exosite 1-Directed Antibody, With Apixaban for Thromboprophylaxis After Elective Knee Replacement Surgery: Text-TKR Study

Cited by 1 publication

References 0 publications

Pharmacological Profile of JNJ-64179375: A Novel, Long-Acting Exosite-1 Thrombin Inhibitor

Pharmacological Profile of JNJ-64179375: A Novel, Long-Acting Exosite-1 Thrombin Inhibitor

Contact Info

Product

Resources

About